FDA Clears GSK Drug That Could Change How Certain Rectal Cancers Are Treated
FDA approves GSK's Jemperli as first immunotherapy for dMMR/MSI-H rectal cancer, offering a surgery-free alternative.
Share
Why It Matters
GSK got government approval for a new cancer medicine. This is good news because it shows the company made something doctors really needed.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.